Artwork

Content provided by Johns Hopkins Kimmel Cancer Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Johns Hopkins Kimmel Cancer Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Cancer Matters with Dr Bill Nelson - FDA Approval of a Drug Targeting a Brain Cancer Mutation

13:17
 
Share
 

Manage episode 433007019 series 2310018
Content provided by Johns Hopkins Kimmel Cancer Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Johns Hopkins Kimmel Cancer Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr Bill Nelson talks with Dr Matthias Holdhoff about the treatment of brain cancer and a significant FDA approval of a new drug treatment for a type of brain cancer, called low-grade glioma. The drug, called vorasidenib, is a targeted cancer therapy that works by inhibiting the activity of a mutated gene called IDH, slowing the growth of the cancer. Read more here

  continue reading

119 episodes

Artwork
iconShare
 
Manage episode 433007019 series 2310018
Content provided by Johns Hopkins Kimmel Cancer Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Johns Hopkins Kimmel Cancer Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr Bill Nelson talks with Dr Matthias Holdhoff about the treatment of brain cancer and a significant FDA approval of a new drug treatment for a type of brain cancer, called low-grade glioma. The drug, called vorasidenib, is a targeted cancer therapy that works by inhibiting the activity of a mutated gene called IDH, slowing the growth of the cancer. Read more here

  continue reading

119 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide